HOLDRs Pharmaceutical (PPH) Buy, Sell or Hold

HOLDRs Pharmaceutical (PPH)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

0.00

-0.00 (0.00%)

1 watching

COMMENT

If you like the biotechnology/pharmaceutical sector, this is a good ETF. One of the ways investors tend to do that kind of a trade is to buy a small portion of the portfolio in the ETF itself and sprinkler around it 2 or 3 stocks that they think will do quite well.

PAST TOP PICK

(Past top pick December 5, up 11%) Will continue to play out.

PAST TOP PICK

(A top pick Sept 3/03. Up 2%.) Feels that 2004 will be a better time for pharmaceuticals. The stock is a good way for investors to lower their risk and play a decent value situation.

TOP PICK

A diversified way he can play the pharmaceutical sector. Good exposure for retail investors. This is a 1 to 3 year play.

Showing 1 to 4 of 4 entries

HOLDRs Pharmaceutical (PPH) Frequently Asked Questions

What is HOLDRs Pharmaceutical stock symbol?

HOLDRs Pharmaceutical is a OTC stock, trading under the symbol PPH (previously PPH-N on Stockchase) on the undefined (undefined). It is usually referred to as or PPH

Is HOLDRs Pharmaceutical a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on PPH (previously PPH-N on Stockchase) on Stockchase. Read the latest expert commentary for HOLDRs Pharmaceutical.

Is HOLDRs Pharmaceutical a good investment or a top pick?

HOLDRs Pharmaceutical was recommended as a Top Pick by Brad Willock on 2003-09-03. Read the latest stock experts ratings for HOLDRs Pharmaceutical.

Why is HOLDRs Pharmaceutical stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for HOLDRs Pharmaceutical.

Is HOLDRs Pharmaceutical worth watching?

HOLDRs Pharmaceutical is covered by Stockchase experts and is worth watching.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

HOLDRs Pharmaceutical (PPH)